Skip to main content
SpringerLink
Log in

Evaluating the quality of life associated with rifabutin prophylaxis forMycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques

  • Research Papers
  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Our objective was to evaluate the effect of rifabutin prophylaxis in patients with AIDS and CD4 counts of less than 200 per cubic millimetre using a combination of Q-TWIST (quality-adjusted time without symptoms and toxicity) and multiattribute health utility assessment. The design consisted of a secondary analysis of two previously reported multicentre, randomized, placebo-controlled clinical trials conducted in 78 academic, community and Department of Veterans Affairs HIV centres and private practices. 542 patients with AIDS and CD4 counts of less than 200 per cubic millimetre were assigned to rifabutin 300 mg/day and 562 were assigned to a placebo. A modified Q-TWiST approach was used for comparing treatments based on the occurrence and duration of time with and without severe symptoms and clinical endpoints. Health states were constructed to represent combinations of clinical events experienced by study patients. Five physicians assigned utilities for health states using a six-attribute health classification system. These utilities were used to adjust survivial for QOL. The rifabutin and placebo groups were compared using estimated quality-of-life-adjusted days. The incidence of MAC was 9% for the rifabutin group and 18% for the placebo group (p<0.001). Differences, although not statistically significant, were observed for rates of survival and hospitalization. The rifabutin group experienced less anaemia (p<0.02), and fever and night sweats (p<0.02) than the placebo group. Average Q-TWiST days were 325 for the rifabutin group and 309 for the placebo group (p<0.05). Q-TWiST days were significantly lower for patients with MAC bacteraemia (p<0.04) and hospitalizations (p<(0.003). Rifabutin prophylaxis resulted in fewer MAC infections and greater quality-of-life-adjusted days of survival compared to no rifabutin. Quality-of-life-adjusted survival, based on a combination of the Q-TWiST and multiattribute health utility index, is a feasible approach for evaluating the outcomes of medical treatment. Future studies should, however, use patient-assigned utility weights to compute Q-TWiST scores, since physician generated utilities may differ significantly from those of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nightingale SD, Jockusch JD, Haslund I, et al. Prognosis of CD4 counts in HIV positive patients. In:Abstracts of the Eighth International Conference on AIDS, Amsterdam, July 19–24, 1992, Vol. 2. Amsterdam: CONGREX, 1992: B169. [Abstract]

    Google Scholar 

  2. Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of disseminatedMycobacterium avium complex infection in AIDS.J Infect Dis 1991;164: 994–998.

    Google Scholar 

  3. Chaisson RE, Moore RD, Richman DD, et al. Incidence and natural history ofMycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine.Am Rev Respir Dis 1992;146: 285–289.

    Google Scholar 

  4. Havlik JA, Horsburgh CR, Metchock B, et al. DisseminatedMycobacterium avium complex infection: clinical identification and epidemiologic trends.J Infect Dis 1992;165: 577–580.

    Google Scholar 

  5. Horsburgh CR Jr.Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.N Engl J Med 1991;324 1332–1338.

    Google Scholar 

  6. Horsburgh CR Jr, Havlik JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminatedMycobacterium avium complex infection with and without antimycobacterial chemotherapy.Am Rev Respir Dis 1991;144: 557–559.

    Google Scholar 

  7. Young LS.Mycobacterium avium complex infection.J Infect Dis 1988;157: 863–867.

    Google Scholar 

  8. Young LS, Wiviott L, Wu M, et al. Azithromycin for treatment ofMycobacterium avium-intracellulare complex infection in patients with AIDS.Lancet 1991;338: 1107–1109.

    Google Scholar 

  9. Hoy J, Mijch A, Sandlum M, et al. Quadruple-drug therapy forMycobacterium avium intracellulare bacteremia in AIDS patients.J Infect Dis 1990;161: 801–805.

    Google Scholar 

  10. Benson CA, Kessler HA, Pottage JC Jr, Trenholme GM. Successful treatment of acquired immunodeficiency syndrome-relatedMycobacterium avium complex disease with a multiple drug regimen including amikacin.Arch Intern Med 1991;151: 582–585.

    Google Scholar 

  11. Chaisson RE, Benson C, Dube M, et al. Clairithromycin therapy for disseminatedMycobacterium avium-complex (MAC) in AIDS. In:Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 10–14, 1992. Washington, DC: American Society for Microbiology, 1992: 891. [Abstract]

    Google Scholar 

  12. Chiu J, Nussbaum J, Bozzette S, et al. Treatment of disseminatedMycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin.Ann Intern Med 1990;113: 358–361.

    Google Scholar 

  13. Kemper CA, Meng TC, Nussbaum J, et al. Treatment ofMycobacterium avium complex bacteremia in AIDS with four-drug oral regimen.Ann Intern Med 1992;116: 466–472.

    Google Scholar 

  14. Kerlikowske KM, Katz MH, Chan AK, Perez-Stable EJ. Antimycobacterial therapy for disseminatedMycobacterium avium complex infection in patients with acquired immunodeficiency syndrome.Arch Intern Med 1992;152: 813–817.

    Google Scholar 

  15. Nightingale SD, Cameron DW, Gordin FM, et al. Two placebo controlled trials of rifabutin prophylaxis againstMycobacterium avium complex in AIDS patients.N Engl J Med 1993;329: 828–833.

    Google Scholar 

  16. Simpson KN, LaVallee RL, Revicki DA.Cost effectiveness of rifabutin for the prevention of Mycobacterium avium complex in AIDS patients. Washington, DC: Battelle Medical Technology Assessment and Policy Research Center, 1993.

    Google Scholar 

  17. Revicki DA, Rothman M, Luce BR. Health-related quality of life assessment and the pharmaceutical industry:Pharmacoeconomics 1992;1: 394–408.

    Google Scholar 

  18. Guyatt GH, Feeny DH, Patrick DL. Measuring healthrelated quality of life. Ann Intern Med 1993;118: 622–629.

    Google Scholar 

  19. Wu AW, Rubin HR. Measuring health status and quality of life in HIV and AIDS.Psychology and Health 1992;6: 251–264.

    Google Scholar 

  20. Gelber RD, Lenderking WR, Cotton DL, et al. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection.Ann Intern Med 1992;116: 961–966.

    Google Scholar 

  21. Wu AW, Mathews WC, Brysk LT, et al.. Quality of life in placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex in AIDS clinical trials.J Acquire Immune Defic Synd 1990;3: 683–690.

    Google Scholar 

  22. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with HIV infection.Med Care 1991;29: 786–798.

    Google Scholar 

  23. Hays RD, Shapiro MF. An overview of generic healthrelated quality of life measures for HIV research.Qual Life Res 1992;1: 91–98.

    Google Scholar 

  24. Lubeck DP, Fries JF. Health status among persons infected with human immunodeficiency virus: a community-based study.Med Care 1992;31: 269–276.

    Google Scholar 

  25. Ganz PA, Coscarelli-Schag CA, Kahn B, Petersen L. Hirji K. Describing the health-related quality of life impact of HIV infection: findings from a study using the HIV overview of problems-evaluation system (HOPES).Qual Life Res 1993;2: 109–119.

    Google Scholar 

  26. Wu AW, Rubin HR, Mathews WC, et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early AIDS-related complex.J Acquir Immune Defic Syndr 1993;6: 452–458.

    Google Scholar 

  27. Gelber RD, Goldhirsch A. A new end point for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.J Clin Oncol 1986;4: 1772–1779.

    Google Scholar 

  28. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-lifeadjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group.Ann Intern Med 1991;114 621–628.

    Google Scholar 

  29. Torrance GW, Zhang Y, Feeny DH, et al.Multi-attribute preference functions for a comprehensive health status classification system. Hamilton, Ontario: Centre for Health Economics and Policy Analysis, McMaster University, 1992.

    Google Scholar 

  30. Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).Am Rev Respir Dis 1989;139: 4–7.

    Google Scholar 

  31. Masur H, Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium Avium Complex. Recommendations on prophylaxis and therapy for disseminatedMycobacterium avium complex disease in patients infected with the human immunodeficiency virus.N Engl J Med 1993;329: 898–904.

    Google Scholar 

  32. Revicki DA, Brown RE, Henry DH, et al. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia.J Acquir Immune Def Syndr 1994;7: 474–484.

    Google Scholar 

  33. Torrance GW. Utility approach to measuring healthrelated quality of life.J Chron Dis 1987;40: 593–600.

    Google Scholar 

  34. Torrance GW, Feeny DH. Utilities and quality-adjusted life years.Int J Technol Assess Health Care 1989;5: 559–575.

    Google Scholar 

  35. Feeny DH, Furlong WJ, Barr RD, et al. A comprehensive multi-attribute system for classifying the health status of survivors of childhood cancer.J Clin Oncol 1992;10: 923–928.

    Google Scholar 

  36. Justice AC, Feinstein AR, Wells CK. A new prognostic staging system for the acquired immunodeficiency syndrome.N Engl J Med 1989;320: 1388–1393.

    Google Scholar 

  37. Rabeneck L, Crane MM, Risser JM, et al. A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats.J Gen Intern Med 1993;8: 5–9.

    Google Scholar 

  38. Mulley AG. Assessing patients' utilities: can the ends justify the means?Med Care 1989;27(Suppl): S269-S281.

    Google Scholar 

  39. Froberg DG, Kane RL. Methodology for measuring health-state preferences-III: population and context effects.J Clin Epidemiol 1989;42: 585–592.

    Google Scholar 

  40. Damiano AM.Further Development and Evaluation of the Functional Capacity Index. Baltimore: School of Hygiene and Public Health, Johns Hopkins University, 1993. [Unpublished doctoral dissertation]

    Google Scholar 

  41. Revicki DA. Health care technology assessment and health-related quality of life. In: D Banta, BR Luce.Health Care Technology and Its Assessment: An International Perspective. New York: Oxford University Press, 1993.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Technology Assessment and Policy Research Program, Battelle Centers for Public Health Research and Evaluation, 2101 Wilson Boulevard, Suite 800, 22201, Arlington, USA

    D. A. Revicki, K. N. Simpson & R. L. LaVallee

  2. Department of Health Policy and Administration, University of North Carolina, Chapel Hill, NC

    D. A. Revicki, K. N. Simpson & R. L. LaVallee

  3. Departments of Health Policy and Management and Internal Medicine, Johns Hopkins University, Baltimore, MD

    A. W. Wu

Authors
  1. D. A. Revicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. N. Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. W. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. L. LaVallee
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This research was supported in part by a grant from Adria Laboratories.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Revicki, D.A., Simpson, K.N., Wu, A.W. et al. Evaluating the quality of life associated with rifabutin prophylaxis forMycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques. Qual Life Res 4, 309–318 (1995). https://doi.org/10.1007/BF01593883

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01593883

Key words

Search

Navigation